ReviewBMC neurology2026
MELAS syndrome complicated by anti-GFAP autoantibody positivity: a case report and literature review.
Review in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundAutoimmune abnormalities have been reported in mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome, but anti-glial fibrillary acidic protein (GFAP) antibody positivity in both serum and cerebrospinal fluid (CSF) has not been previously described. We report such a case and review the literature on MELAS-associated autoimmune abnormalities. CASE PRESENTATION: A 46-year-old man presented with hearing loss, aphasia, and psychiatric symptoms. Brain magnetic resonance imaging (MRI) showed bilateral temporo-parietal lesions. Anti-GFAP antibodies were detected in both serum and CSF. Despite multiple immunotherapies including immunoglobulin, methylprednisolone, and cyclophosphamide, the patient showed minimal clinical improvement. Genetic testing revealed m.3243 A > G mutation (11.91% heteroplasmy), confirming MELAS syndrome. The patient died within three months of onset.
conclusionsTo our knowledge, this is the first report of MELAS syndrome with concurrent serum and CSF anti-GFAP antibody positivity. This case expands the spectrum of autoimmune abnormalities observed in MELAS syndrome. Together with our literature review, this case suggests that mitochondrial dysfunction may trigger various secondary autoimmune responses. The clinical significance and pathogenic role of these autoantibodies in MELAS syndrome warrant further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.